Address: Aras 1-7, Blok C4 & C5, Kompleks C, Pusat Pentadbiran Kerajaan Persekutuan, 62662 Putrajaya, Wilayah Persekutuan,Malaysia
Tel: 8885 8000
The Ministry of Technology, Research and Innovation (MOSTI) is the Malaysian ministry in charge of research, telecommunication and information technology. The current minister is Datuk Dr. Maximus Ongkili.
MOSTI was first established in 1973 as the Ministry of Technology, Research and Local Government. Additional responsibility as the lead agency pertaining to environmental matters, the ministry then assumed its name Ministry of Science, Technology and Environment (MOSTE) in 1976. The formation of MOSTI came after the restructuring of MOSTE following the Cabinet decision on March 27, 2004.
In February 2007 were introduced a cluster approach (Biotechnology, ICT, Industry, Sea to Space and S&T Services). The National Innovation Model 2007 was introduced as well.
The objectives of the ministry are to move the economy up the value chain and raise the country’s capacity for knowledge, creativity and innovation and nurture first class mentality, which implies:
Increase productivity and competitiveness in agriculture, manufacturing and services sectors
Generate new sources of wealth in technology and knowledge-intensive sectors
Knowledge and innovation will be key determinants of Malaysia’s success as a KBE
Enhance innovation system that encourages top quality R&D and its commercialisation
MOSTI controls and supervises a number of institutions that are responsible in providing technical services to the government and the public. Besides divisions and agencies of the federal government, MOSTI also supervises companies set up by the government or through incorporation of a government body:
MIMOS Bhd (MIMOS)
Multimedia Development Corporation (MDeC)
SIRIM Bhd (SIRIM)
Technology Park Malaysia Corporation Sdn Bhd (TPM)
Malaysia Biotechnology Corporation (MBC)
Astronautic Technology Sdn Bhd (ATSB)
National ICT Security and Emergency Response Centre (NISER)
Malaysia Network Information Centre (MYNIC)
Malaysian Technology Development Corporation (MTDC)
“Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of…
“Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of…
“Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of…
Klinsel’s CEO discusses the company’s ambitions of growth in a very competitive CRO market and stresses that local experience is truly a distinguishing factor and this is why they are…
Novo Nordisk Malaysia’s general manager shares the ongoing fight to cure diabetes and talks about the necessity to raise awareness, with for instance their current MoU with the ministry of…
Malaysia Healthcare Travel Council’s CEO is proud of her country’s healthcare system and their efforts at attracting medical tourists from all over the world, with the support of the healthcare…
Mundipharma Malaysia’s country manager discusses his company’s aim to become a reference in Malaysia for pain management, on the back of the tremendous 48 percent growth of the business last year. …
Lundbeck’s country manager gives a thorough overview of CNS disorders in Malaysia and states: “It is important to remind everyone that mental health conditions or brain diseases are not to…
MMA’s president shares the reasons why Malaysia is ranked today third in terms of healthcare quality, with a very efficient public system, high quality doctors and strong government support. However,…
IMS in Malaysia is possibly the first company to have signed a Memorandum of Understanding with the government for data provision. IMS Health’s general manager introduces this landmark and also…
Aspen Malaysia’s country manager details the company’s success in the country with a specific business model based on acquiring and remarketing originators. Although Aspen is a renowned generic player, market dynamics…
MGCC’s Executive Director discusses the opportunities and challenges for German pharma and healthcare companies to invest in Malaysia, at a time where most have decided to invest and base their…
See our Cookie Privacy Policy Here
